Uncategorized
Allergan settles Restasis litigation
Allergan has reached a settlement with Famy Care Limited regarding litigation concerning its U.S. patents for Restasis, the company announced in a press release.Under the agreement, Famy Care litigation concerning the patents for Restasis (cyclosporine ophthalmic emulsion 0.05%) will be dismissed and Famy Care will end its pending petitions for inter partes review, while Allergan will allow the company to market a generic version of the drug in the United States beginning Feb. 27, 2024, or earlier under certain conditions.